The antithrombotic effects of statins

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 433-445

  Phillip Owens, A ^a   Mackman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coagulation; Platelets; Thrombomodulin; Tissue factor

Indexed keywords

ACTIVATED PROTEIN C; ATORVASTATIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; CD40 LIGAND; CERIVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MEVINOLIN; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; PROBUCOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; THROMBOMODULIN; THROMBOPLASTIN; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ANTITHROMBOTIC ACTIVITY; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG ACTIVITY; ENZYME ACTIVE SITE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INTRACELLULAR SIGNALING; NONHUMAN; PLATELET REACTIVITY; PLEIOTROPY; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTICOAGULANTS; BLOOD PLATELETS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NF-KAPPA B; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ACTIVATION; PRENYLATION; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; THROMBOPLASTIN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84901501428     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051812-145304     Document Type: Review

References (97)

1. Gordon T, KannelWB. 1971. Premature mortality from coronary heart disease. The Framingham study. JAMA 215(10):1617-25
2. KannelWB, Castelli WP, Gordon T, et al. 1971. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann. Intern. Med. 74(1):1-12
3. Kastelein JJ, Akdim F, Stroes ES, et al. 2008. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14):1431-43 (Pubitemid 351482735)
4. Brandes RP. 2005. Statin-mediated inhibition of Rho: only to get more NO? Circ. Res. 96(9):927-29 (Pubitemid 40712791)
5. Solski PA, Helms W, Keely PJ, et al. 2002. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ. 13(8):363-73
6. Go AS, Mozaffarian D, Roger VL, et al. 2013. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127(1):e6-e245
7. Jurk K, Kehrel BE. 2005. Platelets: physiology and biochemistry. Semin. Thromb. Hemost. 31(4):381-92 (Pubitemid 41362342)
8. Libby P. 1995. Molecular bases of the acute coronary syndromes. Circulation 91(11):2844-50
9. Opper C, Clement C, Schwarz H, et al. 1995. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 113(2):211-17
10. Shastri KM, Carvalho AC, Lees RS. 1980. Platelet function and platelet lipid composition in the dyslipoproteinemias. J. Lipid Res. 21(4):467-72 (Pubitemid 11235483)
11. Levy Y, Gimpel Y, Abutbul L, et al. 1994. An abnormal platelet membrane lipid composition in patients with low and high blood cholesterol. Platelets 5(3):175-76 (Pubitemid 24168280)
12. Hochgraf E, Levy Y, Aviram M, et al. 1994. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism 43(1):11-17 (Pubitemid 24047099)
13. Radomski MW, Rees DD, Dutra A, et al. 1992. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br. J. Pharmacol. 107(3):745-49
14. Laufs U, Gertz K, Huang P, et al. 2000. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31(10):2442-49
15. Haramaki N, Ikeda H, Takenaka K, et al. 2007. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler. Thromb. Vasc. Biol. 27(6):1471-77 (Pubitemid 46809440)
16. Schoenwaelder SM, Hughan SC, Boniface K, et al. 2002. RhoA sustains integrinαIIbß3 adhesion contacts under high shear. J. Biol. Chem. 277(17):14738-46 (Pubitemid 34952545)
17. Casani L, Sanchez-Gomez S, Vilahur G, et al. 2005. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb. Haemost. 94(5):1035-41 (Pubitemid 41645946)
18. Vilahur G, Segales E, Salas E, et al. 2004. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model. Circulation 110(12):1686-93 (Pubitemid 39297994)
19. LaufsU, Liao JK. 1998. Post-transcriptional regulation of endothelial nitric oxide synthasemRNAstability by Rho GTPase. J. Biol. Chem. 273(37):24266-71 (Pubitemid 28435775)
20. Tremoli E, Folco G, Agradi E, et al. 1979. Platelet thromboxanes and serum-cholesterol. Lancet 1(8107):107-8
21. Prisco D, Rogasi PG, Paniccia R, et al. 1988. Altered lipid composition and thromboxane A2 formation in platelets from patients affected by IIa hyperlipoproteinemia. Thromb. Res. 50(5):593-604
22. Notarbartolo A, Davi G, Averna M, et al. 1995. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15(2):247-51
23. Schror K. 1990. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. Eicosanoids 3(2):67-73
24. Pignatelli P, Carnevale R, Pastori D, et al. 2012. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 126(1):92-103
25. Pignatelli P, Carnevale R, Di Santo S, et al. 2011. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler. Thromb. Vasc. Biol. 31(2):423-34
26. Pignatelli P, Sanguigni V, Lenti L, et al. 2007. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J. Thromb. Haemost. 5(6):1170-78 (Pubitemid 46902118)
27. Puccetti L, Santilli F, Pasqui AL, et al. 2011. Effects of atorvastatin and rosuvastatin on thromboxanedependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214(1):122-28
28. Kunjathoor VV, Febbraio M, Podrez EA, et al. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277(51):49982-88 (Pubitemid 36014449)
29. Janabi M, Yamashita S, Hirano K, et al. 2000. Oxidized LDL-induced NF-κB activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36- deficient patients. Arterioscler. Thromb. Vasc. Biol. 20(8):1953-60 (Pubitemid 30648813)
30. Podrez EA, Byzova TV, Febbraio M, et al. 2007. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 13(9):1086-95 (Pubitemid 47517507)
31. Bruni F, Pasqui AL, Pastorelli M, et al. 2005. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin. Appl. Thromb. Hemost. 11(4):417-28 (Pubitemid 41546768)
32. PietschA, ErlW, LorenzRL. 1996. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem. Pharmacol. 52(3):433-39 (Pubitemid 26233586)
33. Owens AP 3rd, Passam FH, Antoniak S, et al. 2012. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemicmice andmonkeys is inhibited by simvastatin. J. Clin. Invest. 122(2):558-68
34. Puccetti L, Pasqui AL, Pastorelli M, et al. 2002. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur. J. Clin. Invest. 32(12):901-8
35. Mackman N, Tilley RE, Key NS. 2007. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 27(8):1687-93 (Pubitemid 47207163)
36. Owens AP 3rd, MackmanN. 2011. Microparticles in hemostasis and thrombosis. Circ. Res. 108(10):1284- 97
37. Wilcox JN, Smith KM, Schwartz SM, et al. 1989. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 86(8):2839-43 (Pubitemid 19112635)
38. Kato K, Elsayed YA, Namoto M, et al. 1996. Enhanced expression of tissue factor activity in the atherosclerotic aortas of cholesterol-fed rabbits. Thromb. Res. 82(4):335-47 (Pubitemid 26180352)
39. Aikawa M, Voglic SJ, Sugiyama S, et al. 1999. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 100(11):1215-22 (Pubitemid 29426598)
40. Annex BH, Denning SM, Channon KM, et al. 1995. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 91(3):619-22
41. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. 1996. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94(12):3090-97 (Pubitemid 26427472)
42. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. 1996. Identification of active tissue factor in human coronary atheroma. Circulation 94(6):1226-32 (Pubitemid 26307246)
43. Tremoli E, CameraM, Toschi V, et al. 1999. Tissue factor in atherosclerosis. Atherosclerosis 144(2):273-83 (Pubitemid 29305462)
44. Ardissino D, Merlini PA, Arlens R, et al. 2000. Tissue factor in human coronary atherosclerotic plaques. Clin. Chim. Acta 291(2):235-40 (Pubitemid 30089767)
45. Hatakeyama K, Asada Y, Marutsuka K, et al. 1997. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 133(2):213-19 (Pubitemid 27373498)
46. Leroyer AS, Isobe H, Leseche G, et al. 2007. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J. Am. Coll. Cardiol. 49(7):772-77 (Pubitemid 46240708)
47. Thiruvikraman SV, Guha A, Roboz J, et al. 1996. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab. Invest. 75(4):451-61 (Pubitemid 26346797)
48. Bochkov VN, Mechtcheriakova D, Lucerna M, et al. 2002. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca++/NFAT. Blood 99(1):199- 206
49. Schuff-Werner P, Claus G, Armstrong VW, et al. 1989. Enhanced procoagulatory activity (PCA) of human monocytes/macrophages after in vitro stimulation with chemically modified LDL. Atherosclerosis 78(2-3):109-12 (Pubitemid 19195480)
50. Drake TA, Hannani K, Fei HH, et al. 1991. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am. J. Pathol. 138(3):601-7
51. Meisel SR, Xu XP, Edgington TS, et al. 2011. Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. J. Atheroscler. Thromb. 18(7):596-603
52. Cui MZ, Penn MS, Chisolm GM. 1999. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J. Biol. Chem. 274(46):32795-802 (Pubitemid 129535312)
53. Petit L, Lesnik P, Dachet C, et al. 1999. Tissue factor pathway inhibitor is expressed by human monocytederived macrophages: relationship to tissue factor induction by cholesterol and oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 19(2):309-15 (Pubitemid 29072744)
54. Ferro D, Basili S, Alessandri C, et al. 1997. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet 350(9086):1222 (Pubitemid 127445098)
55. Ferro D, Basili S, Alessandri C, et al. 2000. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 149(1):111-16 (Pubitemid 30125978)
56. Markle RA, Han J, Summers BD, et al. 2003. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J. Cell. Biochem. 90(1):23-32 (Pubitemid 37052306)
57. Baetta R, Camera M, Comparato C, et al. 2002. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 22(4):692-98 (Pubitemid 34408755)
58. Colli S, Eligini S, Lalli M, et al. 1997. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17(2):265-72 (Pubitemid 27098183)
59. Hilgendorff A, Muth H, Parviz B, et al. 2003. Statins differ in their ability to block NF-κB activation in human blood monocytes. Int. J. Clin. Pharmacol. Ther. 41(9):397-401 (Pubitemid 37138482)
60. Eto M, Kozai T, Cosentino F, et al. 2002. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105(15):1756-59 (Pubitemid 34408880)
61. Kunieda Y, Nakagawa K, Nishimura H, et al. 2003. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb. Res. 110(4):227-34
62. Nagata K, Ishibashi T, Sakamoto T, et al. 2002. Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. Atherosclerosis 163(1):39-47 (Pubitemid 34615724)
63. Guha M, Mackman N. 2002. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 277(35):32124-32 (Pubitemid 34969025)
64. Monetti M, Canavesi M, Camera M, et al. 2007. Rosuvastatin displays anti-atherothrombotic and antiinflammatory properties in apoE-deficient mice. Pharmacol. Res. 55(5):441-49 (Pubitemid 46560397)
65. Bea F, Blessing E, Shelley MI, et al. 2003. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 167(2):187-94 (Pubitemid 36773519)
66. SukhovaGK, Williams JK, Libby P. 2002. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler. Thromb. Vasc. Biol. 22(9):1452-58
67. Cortellaro M, Cofrancesco E, Arbustini E, et al. 2002. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb. Haemost. 88(1):41-47 (Pubitemid 34752265)
68. Glynn RJ, Danielson E, Fonseca FA, et al. 2009. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360(18):1851-61
69. Van de Wouwer M, CollenD, ConwayEM. 2004. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler. Thromb. Vasc. Biol. 24(8):1374-83 (Pubitemid 39050428)
70. Salomaa V, Matei C, Aleksic N, et al. 1999. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353(9166):1729-34 (Pubitemid 29240370)
71. Lin SJ, Hsieh FY, Chen YH, et al. 2009. Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFα-treated human aortic endothelial cells. Histol. Histopathol. 24(9):1147-59
72. Masamura K, Oida K, Kanehara H, et al. 2003. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler. Thromb. Vasc. Biol. 23(3):512-17 (Pubitemid 36337231)
73. Lin SJ, Chen YH, Lin FY, et al. 2007. Pravastatin induces thrombomodulin expression in TNFα-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity. J. Cell. Biochem. 101(3):642-53
74. Morikawa S, Takabe W, Mataki C, et al. 2002. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J. Atheroscler. Thromb. 9(4):178-83
75. Shi J, Wang J, Zheng H, et al. 2003. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alphainduced thrombomodulin downregulation. Blood Coagul. Fibrinolysis 14(6):575-85 (Pubitemid 37083174)
76. Fu Q, Wang J, Boerma M, et al. 2008. Involvement of heat shock factor 1 in statin-induced transcriptional upregulation of endothelial thrombomodulin. Circ. Res. 103(4):369-77
77. Uchiyama T, Atsuta H, Utsugi T, et al. 2006. Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis 188(2):265-73 (Pubitemid 44301130)
78. Uchiyama T, Atsuta H, Utsugi T, et al. 2007. HSF1 and constitutively active HSF1 improve vascular endothelial function (heat shock proteins improve vascular endothelial function). Atherosclerosis 190(2):321- 29
79. Wada H, Mori Y, Kaneko T, et al. 1993. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am. J. Hematol. 44(2):112-16 (Pubitemid 23269717)
80. Malyszko J, Malyszko JS, Hryszko T, et al. 2001. Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal dialysis patients.Am. J. Nephrol. 21(5):373-77 (Pubitemid 34701842)
81. Malyszko J, Malyszko JS, Hryszko T, et al. 2001. Simvastain affects TAFI and thrombomodulin in CAPD patients. Thromb. Haemost. 86(3):930-31 (Pubitemid 32834208)
82. Seljeflot I, Tonstad S, Hjermann I, et al. 2002. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 162(1):179-85 (Pubitemid 34327356)
83. Kolev K, Machovich R. 2003. Molecular and cellular modulation of fibrinolysis. Thromb. Haemost. 89(4):610-21 (Pubitemid 36456958)
84. Myohanen H, VaheriA. 2004. Regulation and interactions in the activation of cell-associated plasminogen. Cell. Mol. Life Sci. 61(22):2840-58 (Pubitemid 40064331)
85. Robbie LA, Booth NA, Brown AJ, et al. 1996. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 16(4):539-45 (Pubitemid 26107725)
86. Cesari M, Sartori MT, Patrassi GM, et al. 1999. Determinants of plasma levels of plasminogen activator inhibitor-1: a study of normotensive twins. Arterioscler. Thromb. Vasc. Biol. 19(2):316-20 (Pubitemid 29072745)
87. Moss AJ, Goldstein RE, Marder VJ, et al. 1999. Thrombogenic factors and recurrent coronary events. Circulation 99(19):2517-22 (Pubitemid 29228281)
88. Meade TW, Ruddock V, Stirling Y, et al. 1993. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342(8879):1076-79 (Pubitemid 23338739)
89. Folsom AR, Pankow JS, Williams RR, et al. 1998. Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb. Haemost. 79(2):400-4 (Pubitemid 28065892)
90. Essig M, Nguyen G, Prie D, et al. 1998. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res. 83(7):683-90 (Pubitemid 28462781)
91. Krysiak R, Okopien B, Herman Z. 2003. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63(17):1821-54 (Pubitemid 37083030)
92. Nawawi H, OsmanNS, Yusoff K, et al. 2003. Reduction in serum levels of adhesionmolecules, interleukin- 6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with nonfamilial hypercholesterolemia. Horm. Metab. Res. 35(8):479-85 (Pubitemid 37204564)
93. Bourcier T, Libby P. 2000. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor- 1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20(2):556-62
94. Kruithof EK. 2008. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb. Haemost. 100(6):969-75
95. Folsom AR. 2001. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb. Haemost. 86(1):366-73 (Pubitemid 32666188)
96. Seljeflot I, Tonstad S, Hjermann I, et al. 2002. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb. Res. 105(4):285-90 (Pubitemid 34621102)
97. Di Garbo V, Bono M, Di Raimondo D, et al. 2000. Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response. Eur. J. Clin. Pharmacol. 56(4):277-84 (Pubitemid 30462923)